Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: Ability of IL-2 to correct NK cell functional defect

Blood

Volumn 104, Issue 2, 2004, Pages 436-443

  Gismondi, Angela ^a   Cifaldi, Loredana ^b   Mazza, Cinzia ^b   Giliani, Silvia ^b   Parolini, Silvia ^b   Morrone, Stefania ^b   Jacobelli, Jordan ^b   Bandiera, Elisabetta ^b   Notarangelo, Luigi ^b   Santoni, Angela ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BETA2 INTEGRIN; CD16 ANTIGEN; CELL CYCLE PROTEIN; F ACTIN; INTERLEUKIN 2; PROTEIN; PROTEIN CDC42; SCAR PROTEIN; TYROSINE; UNCLASSIFIED DRUG; WAVE PROTEIN; WISKOTT ALDRICH SYNDROME PROTEIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DEPENDENT LYMPHOCYTOTOXICITY; ARTICLE; CELL ADHESION; CELL COUNT; CELL FUNCTION; CELL MEDIATED CYTOTOXICITY; CONJUGATION; CONTROLLED STUDY; CYTOSKELETON; CYTOTOXICITY; GENE; GENE MUTATION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; TARGET CELL; THROMBOCYTOPENIA; WASP GENE; X CHROMOSOME LINKED DISORDER;

EID: 3142585003     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2621     Document Type: Article

References (39)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187-376.
2. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol. 2001;1:41-49.
3. Leibson PJ. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity. 1997;6:655-661.
4. Colucci F, Di Santo JP, Leibson PJ. Natural killer cell activation in mice and men: different triggers for similar weapons? Nat Immunol. 2002;3:807-813.
5. Lahier LL. Natural killer cell receptor signaling. Curr Opin Immunol. 2003;15:308-314.
6. Palmieri G, Serra A, De Maria R, et al. Cross-linking of α4β1 and α5β1 fibronectin receptors enhances natural killer cell cytotoxic activity. J Immunol. 1995;155:5314-5322.
7. Helander TS, Carpen O, Turunen O, Kovanen PE, Vaheri A, Timonen T. ICAM-2 redistributed by ezrin as a target for killer cells. Nature. 1996;382: 265-268.
8. Timonen T, Helander TS. Natural killer cell-target interactions. Curr Opin Cell Biol. 1997;9:667-673.
9. Brumbaugh KM, Binstadt BA, Billadeau DD, et al. Functional role for Syk tyrosine kinase in natural killer cell-mediated natural cytotoxicity. J Exp Med. 1997;186:1965-1974.
10. Gismondi A, Jacobelli J, Mainiero F, et al. Cutting edge: functional role for proline-rich tyrosine kinase 2 in NK cell-mediated natural cytotoxicity. J Immunol. 200;164:2272-2276.
11. Perussia B. Signaling for cytotoxicity. Nat Immunol. 2000;5:372-374.
12. Vyas YM, Maniar H, Dupont B. Visualization of signaling pathways and cortical cytoskeleton in cytolytic and noncytolytic natural killer cell immune synapses. Immunol Rev. 2002;189:161-178.
13. Davis DM. Assembly of the immunological synapse for T cells and NK cells. Trends Immunol. 2002;7:356-363.
14. Thrasher AJ. WASp in immune-system organization. Nat Rev Immunol. 2002;2:635-646.
15. Siminovitch KA, Zhang J, Badour K. The Wiskott-Aldrich syndrome protein: forging the link between actin and cell activation. Immunol Rev. 2003;192:98-112.
16. Villa A, Notarangelo L, Macchi P, et al. X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet. 1995;9:414-417.
17. Zhu Q, Watanabe C, Liu T, et al. Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression and phenotype. Blood. 1997;90:2680-2689.
18. Ochs HD, Rosen FS. The Wiskott-Aldrich syndrome. In: Ochs HD, Smith CIE, Puck JM, eds. Primary Immunodeficiency Diseases: A Molecular and Genetics Approach. New York, NY: Oxford University Press; 1999:292-305.
19. Oda A, Ochs HD, Druker BJ, et al. Collagen induces tyrosine phosphorylation of Wiskott-Aldrich syndrome protein in human platelets. Blood. 1998;92:1852-1858.
20. Guinamard R, Aspenstrom P, Fougereau M, Chavrier P, Guillemot JC. Tyrosine phosphorylation of the Wiskott-Aldrich syndrome protein by Lyn and Btk is regulated by CDC42. FEBS Lett. 1998;434:431-436.
21. Baba Y, Nonoyama S, Matsushita M, et al. Involvement of Wiskott-Aldrich protein in B-cell cytoplasmic tyrosine kinase pathway. Blood. 1999; 93:2003-2012.
22. Cory GOC, Garg R, Cramer R, Ridley AJ. Phosphorylation of tyrosine 291 enhances the ability of WASP to stimulate actin polymerization and filopodium formation. J Biol Chem. 2002;277: 45115-45121.
23. Orange JS, Ramesh N, Remold-O'Donnell E, et al. Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc Natl Acad Sci U S A. 2002;999:11351-11356.
24. Giliani S, Fiorini M, Mella P, et al. Prenatal molecular diagnosis of Wiskott-Aldrich syndrome by direct mutation analysis. Prenat Diagn. 1999;19: 36-40.
25. Perussia B, Ramoni C, Anegon I, Cuturi MC, Faust J, Trinchieri G. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. Nat Immun Cell Growth Regul. 1987;6: 171-188.
26. Pross HF, Callerwaert D, Rubin P. Assay for NK cell cytotoxicity-their values and pitfalls. In: Lotzova E, Herberman RB, eds. Immunobiology of Natural Killer Cells. Vol 1. Boca Raton, FL: CRC Press; 1986:2-20.
27. Gismondi A, Jacobelli J, Strippoli R, et al. Proline-rich tyrosine kinase 2 and Rac activation by chemokine and integrin receptors controls NK cell transendothelial migration. J Immunol. 2003;170: 3065-3073.
28. Comans-Bitter WM, de Groot R, van den Beemd R, et al. Immunophenotyping of blood lymphocytes in childhood: reference values for lymphocyte subpopulations. J Pediatr 1997;130:388-393.
29. Finberg RW, Newburger JW, Mikati MA, Heller AH, Burns JC. Effect of high doses of intravenously administered immune globulin on natural killer cell activity in peripheral blood. J Pediatr. 1992;120:376-380.
30. Gismondi A, Mainiero F, Morrone S, et al. Triggering through CD16 or phorbol esters enhances adhesion of NK cells to laminin via very late antigen 6. J Exp Med. 1992;176:1251-1257.
31. Barber DF, Long EO. Coexpression of CD58 or cD48 with intercellular adhesion molecule 1 on target cells enhances adhesion of resting NK cells. J Immunol. 2003;170:294-299.
32. Krawczyk C, Oliveira-dos-Santos A, Sasaki T, et al. Vav1 controls integrin clustering and MHC/peptide-specific cell adhesion to antigen-presenting cells. Immunity. 2002;16:331-343.
33. Linder S, Nelson D, Weiss M, Aepfelbacher M. Wiskott-Aldrich syndrome protein regulates podosomes in primary human macrophages. Proc Natl Acad Sci U S A 1999;96:9648-9653.
34. Burns S, Thrasher AJ, Blundell MP, Machesky L, Jones GE. Configuration of human dendritic cell cytoskeleton by Rho GTases, the WAS protein, and differentiation. Blood. 2001;98:1142-1149.
35. Salcedo TW, Azzoni L, Wolf SF, Perussia B. Modulation of perforin and granzyme messenger RNA expression in human natural killer cells. J Immunol. 1993;151:2511-2520.
36. Molina IJ, Sancho J, Terhorst C, Rosen FS, Remold-O'Donnell E. T cells of patients with the Wiskott-Aldrich syndrome have a restricted defect in proliferative responses. J Immunol. 1993; 151:4383-4390.
37. Snapper SB, Rosen FS, Mizoguchi E, et al. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity. 1998;9:81-91.
38. Weaver AM, Young ME, Lee W-L, Cooper JA. Integration of signals to the Arp2/3 complex. Curr Opin Cell Biol. 2003;15:23-30.
39. Azuma H, Sakata H, Saijyou M, Okuno A. Effect of interleukin 2 on intractable herpes virus infection and chronic eczematoid dermatitis in a patient with Wiskott-Aldrich syndrome. Eur J Pediatr. 1993;152:998-1000.